Modelling cost-benefit of NGS for personalized tuberculosis control in German healthcare services

New genomic technologies such as next-generation sequencing (NGS) may yield information on multiple genetic developments of Mycobacterium tuberculosis (MTB). Basically, NGS allows management of contact investigation to be targeted especially at contacts likely to benefit, thus reducing secondary TB morbidity and follow-up treatment costs in the near future. However, NGS has not been implemented widely, despite of its high-throughput capacity and rapidly decreasing costs of DNA sequencing. Economic evidence could help applying NGS results to epidemiological and clinical practice, but there are several methodologi…